Prestige Consumer Healthcare Toekomstige groei
Future criteriumcontroles 1/6
Prestige Consumer Healthcare zal naar verwachting groeien in winst en omzet met respectievelijk 5% en 2.3% per jaar. De winst per aandeel zal naar verwachting groeien met 5.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.5% zijn.
Belangrijke informatie
5.0%
Groei van de winst
5.7%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 23.7% |
| Inkomstengroei | 2.3% |
| Toekomstig rendement op eigen vermogen | 10.5% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 04 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jun 14Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2027 | 1,190 | 237 | 263 | 279 | 2 |
| 3/31/2026 | 1,160 | 236 | 271 | 284 | 8 |
| 3/31/2025 | 1,131 | 224 | 254 | 260 | 8 |
| 6/30/2024 | 1,113 | 205 | 246 | 256 | N/A |
| 3/31/2024 | 1,125 | 209 | 239 | 249 | N/A |
| 12/31/2023 | 1,134 | -81 | 232 | 241 | N/A |
| 9/30/2023 | 1,127 | -82 | 216 | 224 | N/A |
| 6/30/2023 | 1,130 | -84 | 211 | 220 | N/A |
| 3/31/2023 | 1,128 | -82 | 222 | 230 | N/A |
| 12/31/2022 | 1,109 | 210 | 225 | 234 | N/A |
| 9/30/2022 | 1,108 | 209 | 236 | 245 | N/A |
| 6/30/2022 | 1,095 | 203 | 240 | 249 | N/A |
| 3/31/2022 | 1,087 | 205 | 250 | 260 | N/A |
| 12/31/2021 | 1,058 | 189 | 245 | 256 | N/A |
| 9/30/2021 | 1,022 | 179 | 224 | 239 | N/A |
| 6/30/2021 | 983 | 179 | 209 | 230 | N/A |
| 3/31/2021 | 943 | 165 | 213 | 236 | N/A |
| 12/31/2020 | 957 | 166 | 207 | 233 | N/A |
| 9/30/2020 | 960 | 163 | 218 | 241 | N/A |
| 6/30/2020 | 960 | 152 | 222 | 240 | N/A |
| 3/31/2020 | 963 | 142 | 203 | 217 | N/A |
| 12/31/2019 | 953 | -34 | 199 | 212 | N/A |
| 9/30/2019 | 953 | -34 | 186 | 197 | N/A |
| 6/30/2019 | 954 | -36 | 176 | 186 | N/A |
| 3/31/2019 | 976 | -36 | 179 | 189 | N/A |
| 12/31/2018 | 991 | 64 | 183 | 193 | N/A |
| 9/30/2018 | 1,020 | 340 | 184 | 197 | N/A |
| 6/30/2018 | 1,039 | 340 | 199 | 212 | N/A |
| 3/31/2018 | 1,041 | 340 | N/A | 210 | N/A |
| 12/31/2017 | 1,026 | 390 | N/A | 163 | N/A |
| 9/30/2017 | 972 | 107 | N/A | 156 | N/A |
| 6/30/2017 | 929 | 109 | N/A | 151 | N/A |
| 3/31/2017 | 882 | 69 | N/A | 149 | N/A |
| 12/31/2016 | 849 | 72 | N/A | 179 | N/A |
| 9/30/2016 | 833 | 69 | N/A | 185 | N/A |
| 6/30/2016 | 824 | 68 | N/A | 182 | N/A |
| 3/31/2016 | 806 | 100 | N/A | 176 | N/A |
| 12/31/2015 | 788 | 110 | N/A | 189 | N/A |
| 9/30/2015 | 786 | 103 | N/A | 190 | N/A |
| 6/30/2015 | 761 | 88 | N/A | 170 | N/A |
| 3/31/2015 | 715 | 78 | N/A | 156 | N/A |
| 12/31/2014 | 668 | 70 | N/A | 135 | N/A |
| 9/30/2014 | 615 | 52 | N/A | 113 | N/A |
| 6/30/2014 | 601 | 69 | N/A | 118 | N/A |
| 3/31/2014 | 597 | 73 | N/A | 112 | N/A |
| 12/31/2013 | 609 | 76 | N/A | 118 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei PBH ( 5% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van PBH ( 5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van PBH zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van PBH ( 2.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van PBH ( 2.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen PBH zal naar verwachting over 3 jaar laag zijn ( 10.5 %).